指南与共识泌尿生殖技术与安全MRCTUS

ACR适宜性标准:前列腺癌治疗前检测、监测与分期

ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.
指南 / 共识 · J Am Coll Radiol · 2017-01-01

美国放射学会适宜性标准针对前列腺癌基线评估、监测与分期的影像检查适宜性给出循证推荐。指南采用RAND/UCLA适宜性方法与GRADE对特定临床场景的影像与治疗流程进行评分,证据不足时以专家意见补充。多参数MRI用于局部评估,骨闪烁显像与CT主要用于活检中危或高危患者的骨与淋巴结转移检测。

要点

  • 多参数MRI是前列腺癌局部评估的有力且相对准确的工具,MRI靶向活检需先做多参数MRI。
  • 骨闪烁显像与CT主要用于活检提示中危或高危患者的骨与淋巴结转移检测。
  • 前列腺癌基线评估的核心目标是确定疾病存在、范围(局部与远处)及侵袭性。

核心结论

  • 前列腺癌基线评估的主要目标是确定疾病存在、范围(局部与远处)及侵袭性;多参数MRI已发展为局部评估的有力且相对准确的工具,骨闪烁显像与CT主要用于活检中危或高危患者的骨与淋巴结转移检测。

研究设计与样本

  • 美国放射学会适宜性标准为针对特定临床情况的循证指南,由多学科专家小组每年审阅;制定与修订包括对同行评议期刊当前医学文献的广泛分析,并应用RAND/UCLA适宜性方法与GRADE对特定临床场景的影像与治疗流程适宜性进行评分;证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像或治疗。

诊断标准与关键数值

  • 前列腺癌通常在前列腺特异性抗原水平可疑或直肠指检发现异常后诊断。
  • 组织学诊断可通过经直肠超声引导活检或MRI靶向活检获得,后者需先做多参数MRI。
  • 骨闪烁显像与CT主要用于活检中危或高危患者的骨与淋巴结转移检测。

临床应用与阅片要点

  • 多参数MRI用于前列腺癌局部评估,MRI靶向活检前需先行多参数MRI。
  • 对活检提示中危或高危的患者,使用骨闪烁显像与CT检测骨与淋巴结转移。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Despite the frequent statement that "most men die with prostate cancer, not of it," the reality is that prostate cancer is second only to lung cancer as a cause of death from malignancy in American men. The primary goal during baseline evaluation of prostate cancer is disease characterization, that is, establishing disease presence, extent (local and distant), and aggressiveness. Prostate cancer is usually diagnosed after the finding of a suspicious serum prostate-specific antigen level or digital rectal examination. Tissue diagnosis may be obtained by transrectal ultrasound-guided biopsy or MRI-targeted biopsy. The latter requires a preliminary multiparametric MRI, which has emerged as a powerful and relatively accurate tool for the local evaluation of prostate cancer over the last few decades. Bone scintigraphy and CT are primarily used to detect bone and nodal metastases in patients found to have intermediate- or high-risk disease at biopsy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Coakley FV, Oto A, Alexander LF, et al. ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol. 2017. PMID: 28473080. doi:10.1016/j.jacr.2017.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。